

PHARMACEUTICAL 2023

Arcus Biosciences Inc. Rank 75 of 446









RealRate



Arcus Biosciences Inc. Rank 75 of 446

The relative strengths and weaknesses of Arcus Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Arcus Biosciences Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 4.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 179% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,067,000
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	193,000
Liabilities, Non-Current	0
Other Assets	243,000
Other Compr. Net Income	-6,000
Other Expenses	1,000
Other Liabilities	0
Other Net Income	14,000
Other Revenues	112,000
Property and Equipment	35,000
Research and Development	288,000
Selling, General and Administrative Expense	104,000

Output Variable	Value in 1000 USD
Assets	1,345,000
Liabilities	193,000
Expenses	393,000
Revenues	112,000
Stockholders Equity	1,152,000
Net Income	-267,000
Comprehensive Net Income	-270,000
Economic Capital Ratio	223%

